European Medicines Agency Validates Gilead's Marketing Application for Elvitegravir for Treatment of HIV Infection
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its Marketing Authorisation Application (MAA) for elvitegravir, an integrase inhibitor for the treatment of HIV-1 infection in treatment-experienced patients, has been validated by the European Medicines Agency (EMA). Gilead submitted the MAA on May 22, 2012. Review of the MAA will be conducted under the centralized licensing procedure, which, when finalized, provides one marketing authorization in all 27 member states of the European Union (EU).
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.